ARDX — Ardelyx, Inc. Stock Price, Chart & AI Report

Positive Feb 5, 2026 • 13:00 UTC GlobeNewswire Inc. • Na

Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

Ardelyx, Inc. announced it will hold a conference call on February 19, 2026, to discuss full year and fourth quarter 2025 financial results and provide a business update. The call will feature commentary from executive leadership including CEO Mike Raab and CFO Sue Hohenleitner. The company has two FDA-approved commercial products (IBSRELA and XPHOZAH) and is advancing IBSRELA in Phase 3 development for chronic idiopathic constipation.

ARDX financial results conference call IBSRELA XPHOZAH tenapanor chronic idiopathic constipation Phase 3 trial

Sentiment note

Company is progressing with Phase 3 clinical trials, has two FDA-approved commercial products generating revenue, and is actively advancing its pipeline. The announcement of a scheduled earnings call and ongoing development activities indicate operational momentum and investor engagement.

Positive Jan 23, 2026 • 17:56 UTC GlobeNewswire Inc. • Equity Insider

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.

AVAI MNKD VRTX FATE cell encapsulation technology regenerative medicine FDA approval CAR T-cell therapy

Sentiment note

Real-world evidence studies of XPHOZAH demonstrate patient satisfaction with 45.3% achieving at least 1 mg/dL serum phosphate reduction and 63% of patients reporting improved phosphate control, supporting commercial viability in kidney disease market.

Neutral Jun 2, 2025 • 17:50 UTC GlobeNewswire Inc. • N/A

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - CABO

Cable One reported disappointing Q1 2025 earnings, missing analyst expectations and suspending its dividend. The stock price fell over 40% on this news, leading Pomerantz LLP to investigate potential securities fraud or other unlawful business practices by the company and its officers/directors.

CABO ARDX IART Cable One Ardelyx Integra LifeSciences

Sentiment note

The article mentions an investigation by Pomerantz LLP on behalf of Ardelyx investors, but does not provide any details on the specific issues or concerns.

Positive May 21, 2025 • 12:00 UTC GlobeNewswire Inc. • N/A

Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Ardelyx, a biopharmaceutical company, announced that it will present data supporting its product IBSRELA (tenapanor) at the Digestive Disease Week 2025 Conference.

ARDX Ardelyx IBSRELA tenapanor Digestive Disease Week 2025

Sentiment note

The article highlights Ardelyx's progress in presenting data supporting its product IBSRELA, which suggests the company is actively advancing its pipeline and commercialization efforts.

Positive Apr 24, 2025 • 12:01 UTC GlobeNewswire Inc. • N/A

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Ardelyx, a biopharmaceutical company, announced that it will present data on its IBS-C drug IBSRELA and results from the IBS in America 2024 survey at the upcoming Digestive Disease Week Conference.

ARDX IBSRELA tenapanor IBS-C Digestive Disease Week

Sentiment note

The article highlights Ardelyx's upcoming presentations at a major medical conference, showcasing the company's progress in developing and commercializing its IBS-C drug IBSRELA.

Positive Feb 19, 2025 • 13:01 UTC GlobeNewswire Inc. • Ardelyx, Inc.

Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Ardelyx, a biopharmaceutical company, announced that it will present at the TD Cowen's 45th Annual Health Care Conference on March 3, 2025. The company has two commercial products approved in the U.S. and has agreements for the development and commercialization of its product tenapanor outside the U.S.

ARDX KYKOY Ardelyx biopharmaceutical tenapanor hyperphosphatemia IBSRELA XPHOZAH

Sentiment note

The article highlights Ardelyx's progress in developing and commercializing its products, which suggests a positive outlook for the company.

Positive Jan 6, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Ardelyx, a biopharmaceutical company, announced that its President and CEO, Mike Raab, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.

ARDX Ardelyx biopharmaceutical J.P. Morgan Healthcare Conference

Sentiment note

The article announces that Ardelyx's CEO will present at a major industry conference, which suggests the company is actively engaged in its business and has a positive outlook.

Positive Nov 5, 2024 • 13:00 UTC GlobeNewswire Inc. • N/A

Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

Ardelyx, a biopharmaceutical company, announced that its executives will participate in a fireside chat at the 2024 Jefferies London Healthcare Conference on November 19, 2024.

ARDX Ardelyx Jefferies London Healthcare Conference tenapanor

Sentiment note

The article highlights Ardelyx's participation in an industry conference, which suggests the company is actively engaged in its business activities and seeking to share updates with investors.

Negative Oct 13, 2024 • 11:41 UTC GlobeNewswire Inc. • N/A

ARDX DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX

Rosen Law Firm is encouraging investors who purchased Ardelyx, Inc. securities between October 31, 2023 and July 1, 2024 to secure counsel before the October 15, 2024 deadline in a securities class action lawsuit. The lawsuit alleges that Ardelyx made materially false and misleading statements regarding its future revenue, funding requirements, and the commercial success of its phosphorus inhibitor, XPHOZAH.

ARDX Ardelyx securities class action XPHOZAH

Sentiment note

The article discusses a securities class action lawsuit against Ardelyx, alleging that the company made materially false and misleading statements about its business, which led to investor losses.

Negative Oct 8, 2024 • 21:01 UTC GlobeNewswire Inc. • Holzer & Holzer, Llc

SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors of the October 15, 2024 Lead Plaintiff Deadline in Class Action Lawsuits Filed on Behalf of Symbotic Inc. (SYM), Ardelyx, Inc. (ARDX), PDD Holdings Inc. (PDD), and Sprinklr, Inc. (CXM) Shareholders

Holzer & Holzer, LLC reminds investors of the October 15, 2024 lead plaintiff deadline in class action lawsuits against Symbotic Inc., Ardelyx, Inc., PDD Holdings Inc., and Sprinklr, Inc. The lawsuits allege the companies made false or misleading statements that caused shareholders to purchase their securities at artificially inflated prices.

SYM ARDX PDD CXM Symbotic Inc. Ardelyx, Inc. PDD Holdings Inc. Sprinklr, Inc.

Sentiment note

The lawsuit alleges that the company made misleading statements about its plans to apply for inclusion of its product in a government program, causing the stock price to fall.

Negative Oct 6, 2024 • 11:52 UTC GlobeNewswire Inc. • Rosen, National Trial Lawyers

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important October 15 Deadline in Securities Class Action – ARDX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Ardelyx, Inc. (NASDAQ: ARDX) securities between October 31, 2023 and July 1, 2024 of the important October 15, 2024 lead plaintiff deadline in a securities class action lawsuit.

ARDX Ardelyx securities class action

Sentiment note

The article mentions that a securities class action lawsuit has been filed against Ardelyx, Inc. due to allegedly false and misleading statements made by the company during the class period, which resulted in investor damages.

Positive Oct 2, 2024 • 13:48 UTC GlobeNewswire Inc. • American Kidney Fund

Corporate and Individual Donations Provide Much-Needed Support to Kidney Patients Impacted by Hurricane Helene Through the American Kidney Fund’s Disaster Relief Program

The American Kidney Fund's Disaster Relief Program is providing emergency financial assistance to dialysis and recent transplant patients in areas affected by Hurricane Helene. The program has received generous support from various companies and individual donors to help cover expenses related to lost medications, housing, transportation, and personal essentials.

AUPH ARDX kidney patients hurricane disaster relief donations

Sentiment note

Ardelyx is listed as one of the companies that have provided support to the American Kidney Fund's Disaster Relief Program, suggesting a positive sentiment towards their contribution.